Kopran Limited, a prominent pharmaceutical company, has announced a significant development in its corporate structure. The co-promoters of the company have finalized a family agreement aimed at strengthening the management control of the organization.

Key Details of the Agreement

According to the disclosure made to the stock exchanges, the promoters of Kopran Limited have executed a Memorandum of Family Settlement (MOFS) dated September 1, 2025. This agreement is designed to address long-standing disputes related to shareholding and management rights in various listed and unlisted entities, including Kopran Limited.

Objectives of the Family Settlement

The primary objectives of the MOFS include:

• Resolving family disputes
• Settling inequalities in the partition of family businesses
• Preserving family property by avoiding litigation
• Maintaining the family's honor

Restructuring of Promoter Groups

As per the agreement, the promoters will be categorized into three distinct groups, each representing a branch of the Somani family:

1. The branch led by Mr. Susheel G. Somani
2. The branch comprising the lineal descendants of Late Mr. Rajendra Somani, headed by Mr. Adarsh Somani
3. The branch led by Mr. Surendra Somani

Impact on Management Control

The MOFS is expected to have a significant impact on the management and control of Kopran Limited. Previously, control was exercised jointly by promoters across multiple family branches. Following this agreement, management control will be consolidated and vested solely with the promoters of a single family branch acting together.

Share Transfer and Promoter Classification

The agreement outlines plans for inter-se transfer and purchase of shares among the family branches. Additionally, promoters within each group will be deemed as persons acting in concert. However, the three groups will not be regarded as acting in concert with each other, and their respective rights, obligations, and liabilities will remain separate.

Implications for Shareholders and Investors

While this agreement primarily affects the promoter group, it could have implications for the company's strategic direction and governance. Shareholders and investors should note that this restructuring aims to streamline decision-making processes and potentially lead to more efficient management of the company.

The execution of this family settlement marks a significant milestone in Kopran's corporate journey, potentially paving the way for more focused growth strategies and streamlined operations in the future.

Kopran Limited , a prominent pharmaceutical company, is set to undergo a significant change in its shareholding structure as the promoter group prepares to acquire a 4.18% stake through an inter-family transfer. This move, scheduled for September 1, 2025, aims to resolve family disputes and streamline the company's ownership structure.

Key Details of the Transfer

The acquisition involves 20,15,985 equity shares, representing 4.18% of Kopran Limited's share capital. The transfer will be executed as a gift, without any monetary consideration, among family members. The key acquirers in this transaction include:

1. Varun Somani
2. Vadana Somani
3. Surendra Somani

These individuals will be joined by four associated entities acting in concert:

1. Oriental Enterprises Partnership Firm
2. Panaroma Finvest Private Ltd.
3. Parijat Shipping and Finale Limited
4. Sarvamangal Mercantile Company Ltd.

Transferors and Their Stakes

The shares will be transferred from eight family members, including:

Impact on Promoter Group Shareholding

This inter-family transfer will significantly impact the promoter group's stake in Kopran Limited:

• Before the transaction: The promoter group held 1,10,16,035 shares, representing 22.81% of the total share capital.
• After the transaction: The promoter group's holding will increase to 1,30,32,020 shares, accounting for 26.99% of the total share capital.

Rationale Behind the Transfer

The primary reasons for this inter-family transfer, as stated in the disclosure, are:

1. To resolve family disputes
2. To settle inequalities in the partition of the family business
3. To preserve family property by avoiding litigation
4. To maintain family honor

Regulatory Compliance

The transaction is exempt from open offer requirements under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, specifically under Regulation 10(1)(a)(ii). The acquirers have declared that they will comply with all applicable disclosure requirements as per Chapter V of the SEBI Takeover Regulations.

Market Price Reference

For reference, the 60-day volume-weighted average market price of Kopran Limited's shares was:

• ₹178.65 on the Bombay Stock Exchange (BSE)
• ₹178.70 on the National Stock Exchange (NSE)

This inter-family share transfer marks a significant development for Kopran Limited, potentially leading to a more consolidated ownership structure within the promoter group. Shareholders and market observers will be keenly watching how this change might influence the company's future strategic decisions and performance.